Table 4.
Association of NAFLD, Sarcopenia and the Highest 24-Hour Urinary Sodium Excretion Tertile (T3)
| Variable | Crude | Adjusted model | |||
|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | ||
| Sarcopenia | |||||
| Sarcopenia (–) | Reference | Reference | |||
| Sarcopenia (+) | 1.39 (1.24–1.55) | <0.001 | 1.19 (1.03–1.38) | 0.016 | |
| NAFLD | |||||
| NAFLD (–) | Reference | Reference | |||
| NAFLD (+) | 1.91 (1.76–2.08) | <0.001 | 1.14 (1.01–1.29) | 0.031 | |
| NAFLD×sarcopenia | |||||
| NAFLD (–)×sarcopenia (–) | Reference | Reference | |||
| NAFLD (+)×sarcopenia (–) | 1.89 (1.72–2.07) | <0.001 | 1.16 (1.02–1.31) | 0.027 | |
| NAFLD (–)×sarcopenia (+) | 1.21 (1.01–1.46) | 0.048 | 1.25 (1.01–1.54) | 0.038 | |
| NAFLD (+)×sarcopenia (+) | 2.10 (1.83–2.41) | <0.001 | 1.34 (1.10–1.54) | 0.004 | |
Adjusted model, adjusted for adjusted for age, sex, exercise, smoking, body mass index, hypertension, diabetes, dyslipidemia, aspartate aminotransferase*, alanine aminotransferase*, homeostasis model assessment of insulin resistance*, vitamin D, estimated glomerular filtration rate, Chronic Kidney Disease Epidemiology Collaboration, and appendicular muscle mass.
NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confidence interval.
*Log-transformed.